Clinical Trials Browser

Interventional × LY3295668 erbumine × Thoracic × Clear all

NCT05017025 2025-11-19

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

Lung Neoplasms

NCT03898791 2021-08-05

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Phase 1 Completed

Epilepsy, Small Cell Lung Carcinoma